A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507689-26-00

Acronym

D910DC00001

Enrollment

Registered

2024-03-19

Start date

2019-10-07

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

Brief summary

Recurrence-free survival (RFS)

Detailed description

Overall survival (OS) Time to recurrence (TTR) RFS at 24 months (RFS24) and RFS at 36 months (RFS36) Time from randomization to recurrence/progression on next therapy (RFS2/PFS2)

Interventions

DRUGINFLIXIMAB

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGBEVACIZUMAB

DRUGMYCOPHENOLATE MOFETIL

DRUGDEXTROSE BP

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival (RFS)	—

Secondary

Measure	Time frame
Overall survival (OS) Time to recurrence (TTR) RFS at 24 months (RFS24) and RFS at 36 months (RFS36) Time from randomization to recurrence/progression on next therapy (RFS2/PFS2)	—

Countries

Austria, France, Germany, Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026